3658 results for «391»

Filter By

3658 results

How to treat aortic regurgitation

22 May 2026 – From EuroPCR 2026

Explore cutting-edge transcatheter approaches for aortic regurgitation, including first-in-human ATLAS technique, management in LVAD patients, and off-label Myval use. This session reviews clinical challenges and innovative solutions in aortic valve interventions, offering valuable insights from complex procedural experiences.

Left main complications - Part 3

21 May 2026 – From EuroPCR 2026

This session reviews complex complications encountered in left main coronary interventions. It covers causes and management of acute left main occlusion, critical stenosis of coronary buttons, retrieval techniques for ostial stents, and strategies for managing challenging PCI scenarios that may precipitate or resolve catastrophic events.

Left main complications - Part 3

Left main PCI, what is known and what is new

21 May 2026 – From EuroPCR 2026

This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...

Left main PCI: predictions of risk and long-term clinical outcome

22 May 2026 – From EuroPCR 2026

This session focuses on risk prediction and long-term outcomes following left main percutaneous coronary intervention (PCI). It covers biomarkers like NT-proBNP, hemodynamic predictors, and the impact of comorbidities such as diabetes and chronic kidney disease on patient prognosis over a ten-year follow-up.

Multivessel disease or left main disease

22 May 2026 – From EuroPCR 2026

This session explores revascularisation strategies for patients with multivessel or left main coronary artery disease. It emphasizes the role of intravascular physiology and imaging in guiding treatment decisions and highlights procedural factors that contribute to improved long-term clinical outcomes, supported by complex case discussions.

TAVI interventions for all? From congenital bicuspid valve towards valve-in-valve challenging cases

21 May 2026 – From EuroPCR 2026

This session delves into the complexities of TAVI interventions across diverse challenging cases, including congenital bicuspid valves and valve-in-valve scenarios. It emphasizes complication prevention, decision-making for the Unicorn technique, and the critical role of pre-procedural imaging, illustrated through detailed case studies from Estonia, the Netherlands, and...

When atrial septal closure gets complex

21 May 2026 – From EuroPCR 2026

This session explores the complexities that arise when atrial septal closure procedures become challenging. It covers hybrid retrieval techniques for occluder devices, management of device-related complications mimicking infection, resolution of uncommon complications, and case studies including cryptogenic stroke management in athletes, highlighting procedural intricacies and solutions.

STEMI management around the world

21 May 2026 – From EuroPCR 2026

This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

22 Mar 2022

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Author

Ali Nazmi Calik
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data

GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial

21 Nov 2024

Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.

Edoardo Zancanaro

Author

Edoardo Zancanaro
GLORIOUS

EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI

20 May 2026

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...

EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI

The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

05 Sep 2023

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Lucas Lauder

Author

Lucas Lauder

Author

Felix Mahfoud
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

Aortic stenosis and coronary artery disease: which should be treated first?

18 Jun 2026

In this review, Henryk Dreger explores the complex interplay between aortic stenosis and coronary artery disease, highlighting the latest evidence on PCI timing and its implications for clinical decision-making.

Henryk Dreger

Author

Henryk Dreger
Aortic stenosis and coronary artery disease: which should be treated first?

Transcatheter aortic valve implantation without routine percutaneous coronary intervention: A randomized controlled trial (PRO-TAVI Trial)

29 Mar 2026

Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

Jonathan Curio

Author

Jonathan Curio
TAVI without routine PCI: PRO-TAVI randomized controlled trial

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation

01 Sep 2025

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author

Chiara De Biase
The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]

A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial

03 Apr 2026

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

John Davies

Author

John Davies
Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Sarosh Khan

Author

Sarosh Khan
ORBITA-CTO: Chronic total occlusion PCI in stable angina

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
Didn’t find what you were looking for?